论文部分内容阅读
根治性切除是延长胰腺癌病人生存时间的有效手段,但约40%的病人在初诊时即为局部进展期胰腺癌而失去手术机会。通过制定个体化的新辅助治疗方案,有望使局部进展期胰腺癌降期,从而获得根治性切除的机会。目前,新辅助化疗后序贯放化疗是局部进展期胰腺癌最常见用的新辅助治疗方案,但具体的化疗药物并不统一,吉西他滨联合纳米紫杉醇以及FOLFIRINOX有望成为最佳化疗方案。
Radical resection is an effective means to prolong the survival time of patients with pancreatic cancer, but about 40% of patients at the time of first diagnosis is locally advanced pancreatic cancer and lost the chance of surgery. Through the development of individual neoadjuvant treatment options, is expected to make the local advanced pancreatic cancer down, so as to obtain the chance of radical resection. At present, sequential chemoradiotherapy after neoadjuvant chemotherapy is the most commonly used neoadjuvant therapy for locally advanced pancreatic cancer. However, specific chemotherapy drugs are not uniform. Gemcitabine combined with paclitaxel and FOLFIRINOX are expected to be the best chemotherapy regimens.